• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Do Antenatal Corticosteroids Reduce Morbidity in Premature Neonates Prior to 24 weeks?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Park et al. (Obstetrics & Gynecology, 2017) sought to determine the effectiveness of antenatal corticosteroids prior to 24 weeks gestation

METHODS:

  • Systematic Review and meta-analysis
  • Published randomized or quasi-randomized controlled trials and observational studies including neonates who received antenatal corticosteroids
  • Primary outcome
    • Neonatal mortality up until discharge from the hospital
  • Secondary outcomes
    • Respiratory distress syndrome (RDS), severe intraventricular hemorrhage (grades III and IV), necrotizing enterocolitis (NEC), chronic lung disease at 36 weeks postmenstrual age, retinopathy of prematurity, and neurologic impairment

RESULTS:

  • 17 Studies were included, 3 prospective and 14 retrospective observational studies
  • Data from 3,626 neonates was pooled for the primary outcome
  • The mortality to discharge was 58.1% in the intervention group, compared with 71.8% in the control, with a “moderate” quality of evidence
  • Adjusted odds of mortality to discharge were reduced by 52% in the antenatal corticosteroid group compared to control
    • Adjusted odds ratio 0.48 (95% CI 0.38–0.61)
    • Subgroup analysis of 23 compared to 22 weeks found no difference in mortality to discharge, although small 22 week sample size
  • There were no significant differences between the groups with respect to secondary outcomes
    • Larger sample sizes may be needed to draw firm conclusions around severe morbidities

CONCLUSION:

  • This study indicates that antenatal corticosteroids prior to 24 weeks may reduce neonatal mortality

Learn More – Primary Sources:

Antenatal Corticosteroid Therapy Before 24 Weeks of Gestation: A Systematic Review and Meta-analysis

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Antenatal Corticosteroids – When to Administer?
Is There Value to the Use of Corticosteroids in Women with Short Cervix Who Are Asymptomatic?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site